Last updated: August 1, 2026
Striant was a niche testosterone-replacement product that used a 30 mg mucoadhesive buccal system applied to the gum twice daily. Its commercial opportunity was constrained by administration frequency, oral irritation, physician familiarity with injectable and transdermal testosterone, and competition from lower-cost generic products. The product’s commercial trajectory declined after launch, and Striant is no longer an active growth product in the U.S. pharmaceutical market.
What was Striant and how did it work?
Striant was a testosterone buccal system approved by the U.S. Food and Drug Administration in 2003 under NDA 021306. The product delivered testosterone through the buccal mucosa and was indicated for adult men with testosterone deficiency associated with deficient or absent endogenous testosterone production.[1]
Each system contained 30 mg of testosterone. Patients applied one system to the gum in the morning and a second system approximately 12 hours later. The product was designed to avoid first-pass hepatic metabolism associated with oral testosterone administration.[1]
| Attribute |
Striant |
| Active ingredient |
Testosterone |
| Dosage form |
Mucoadhesive buccal system |
| Strength |
30 mg |
| Administration |
One system twice daily |
| FDA approval |
2003 |
| U.S. NDA |
021306 |
| Primary use |
Male hypogonadism |
| Original sponsor |
Columbia Laboratories, Inc. |
| Commercial status |
Discontinued from active U.S. commercial use |
The dosage form was technically differentiated from testosterone injections, gels, patches and pellets. The differentiation did not translate into durable market share because the product required repeated gum placement and produced local tolerability and adherence challenges.
When did Striant lose commercial exclusivity?
Striant’s commercial exclusivity eroded through a combination of patent aging, limited market penetration and competition from other testosterone-delivery systems. The product did not establish a durable franchise comparable with leading testosterone gels or long-acting injections.
FDA approval in 2003 provided five years of new chemical entity exclusivity, subject to the statutory framework then in effect. That period would have expired in 2008. Any additional protection would have depended on listed patents, pediatric exclusivity and the timing of generic or competing product approvals.
The practical commercial loss of exclusivity occurred before the testosterone market became heavily populated by newer oral, nasal and long-acting delivery products. By the time generic substitution and broader testosterone competition intensified, Striant had limited prescribing momentum.
Striant exclusivity timeline
| Period |
Event |
Commercial impact |
| 2003 |
FDA approval under NDA 021306 |
Entry into the testosterone-replacement market |
| 2003-2008 |
New chemical entity exclusivity period |
Limited immediate generic competition |
| Late 2000s |
Expansion of testosterone gels, injections and patches |
Reduced differentiation |
| 2010s |
Greater payer and physician preference for established products |
Weaker Striant demand |
| Later commercial period |
Product discontinuation |
Loss of active U.S. market position |
What market dynamics affected Striant sales?
Striant entered a testosterone-replacement market with established treatment habits and multiple delivery options. Its central commercial challenge was not the absence of demand for testosterone replacement. It was the difficulty of persuading physicians and patients to select a twice-daily buccal product over more familiar alternatives.
Administration burden
Striant required patients to:
- Apply the system twice daily.
- Place it against the gum in a consistent location.
- Avoid dislodging the system while eating or brushing.
- Monitor local gum and mouth reactions.
- Replace the system after approximately 12 hours.
This regimen created a higher adherence burden than long-acting injections, testosterone pellets or once-daily transdermal products.
Local tolerability
The buccal delivery route created product-specific adverse events, including gum irritation, mouth discomfort, taste disturbance and application-site reactions. These effects weakened repeat use and limited the product’s appeal for patients who wanted a low-maintenance therapy.[1]
Competition from established dosage forms
Striant competed against several classes:
| Product class |
Competitive advantage over Striant |
| Intramuscular testosterone |
Low acquisition cost and established physician familiarity |
| Transdermal gels |
Once-daily administration and broad prescribing experience |
| Transdermal patches |
Familiar systemic delivery with no gum application |
| Testosterone pellets |
Long dosing interval |
| Oral testosterone products |
Convenience for patients who prefer oral administration |
| Nasal testosterone |
Local administration with a different adherence profile |
The market also became more sensitive to testosterone safety monitoring, cardiovascular concerns and regulatory scrutiny. These issues affected the entire category but favored products with larger clinical datasets, greater physician familiarity and stronger payer coverage.
What was Striant’s financial trajectory?
Striant generated limited commercial revenue relative to leading testosterone products. Columbia Laboratories reported Striant revenue as part of its broader corporate reporting, but the company did not establish Striant as a high-growth standalone franchise.
The financial pattern was characterized by:
- Initial commercialization after FDA approval.
- Modest adoption in a crowded category.
- Revenue pressure from competing testosterone formulations.
- Declining commercial relevance as prescribing shifted toward established products.
- Eventual discontinuation and elimination of recurring product revenue.
Public-company reporting from Columbia Laboratories treated Striant as one product within a broader portfolio. The company’s financial performance was therefore influenced by other assets, licensing arrangements, product development expenses and corporate transactions. Standalone Striant revenue is not consistently disclosed in the same format across reporting periods.[2][3]
Revenue exposure
Striant’s revenue exposure was commercially important to Columbia Laboratories because the company had a relatively small product portfolio. Its strategic value was greater for a small specialty pharmaceutical company than its absolute sales were for the overall testosterone market.
The product’s financial limitations included:
- A small addressable population willing to use a buccal system.
- High competition from lower-cost testosterone products.
- Limited opportunity for dose expansion.
- No major indication expansion.
- Lack of a broad prescriber network comparable with large endocrinology and primary-care franchises.
- Product-specific adherence and tolerability issues.
The product was therefore vulnerable to a decline in prescriptions even without immediate generic substitution. In practical terms, commercial erosion began with weak product preference rather than with a single patent event.
What was the competitive position of Striant versus other testosterone products?
Striant had a differentiated delivery mechanism but weak competitive economics.
| Factor |
Striant |
Testosterone gel |
Injectable testosterone |
Testosterone pellets |
| Dosing frequency |
Twice daily |
Usually once daily |
Every several weeks, depending on product |
Several months |
| Administration setting |
Patient self-administered |
Patient self-administered |
Clinic or patient administration |
Physician procedure |
| Local issues |
Gum irritation and oral discomfort |
Skin-transfer and application-site concerns |
Injection pain and peak-trough effects |
Implantation procedure |
| Generic competition |
Limited historical commercial scale |
Significant |
Significant |
More limited |
| Physician familiarity |
Low to moderate |
High |
High |
Moderate |
| Adherence burden |
High |
Moderate |
Low between doses |
Low between procedures |
| Commercial durability |
Weak |
Stronger |
Stronger |
Niche |
Striant’s best theoretical positioning was for men seeking noninjectable treatment who could not tolerate skin products. In practice, the twice-daily oral application limited this niche.
What FDA and Orange Book status applied to Striant?
Striant was approved through the FDA’s NDA pathway, not as a biologic. Biosimilar regulation therefore does not apply. Any competition would arise through generic drug approval, competing branded testosterone products or reformulated testosterone therapies.
The relevant regulatory facts are:
- Striant had an FDA-approved NDA, 021306.[1]
- The product was testosterone, a small-molecule active ingredient.
- FDA labeling covered male hypogonadism associated with inadequate endogenous testosterone production.
- The product was later identified as discontinued in FDA drug-product records.
- Discontinuation was not treated as a withdrawal for safety or efficacy in the FDA discontinued-drug framework.[4]
What is the Orange Book status of Striant?
The Orange Book is the controlling source for current patent and exclusivity listings. Striant’s commercial discontinuation means that any historical patent listing must be analyzed separately from current market availability. A listed patent, if present during the product’s commercial period, would not by itself establish a continuing commercial franchise after product discontinuation.
The key distinction is between:
- FDA approval status,
- commercial availability,
- Orange Book patent listing,
- generic approval status, and
- actual market demand.
For Striant, commercial discontinuation is more significant than residual patent duration. A product with declining prescriptions and no active commercial investment has limited ability to convert patent protection into revenue.
Were there Paragraph IV challenges to Striant?
No major, commercially consequential Paragraph IV litigation campaign is associated with Striant in the public record comparable with high-revenue testosterone gels or blockbuster medicines.
A Paragraph IV certification would challenge the validity, enforceability or infringement of an Orange Book-listed patent. The economic incentive depends on the size of the branded market and the potential value of first generic entry. Striant’s relatively small market and declining commercial position reduced that incentive.
Generic entry risks
The main generic-entry risks were:
- Substitution by generic testosterone injections.
- Substitution by generic testosterone gels.
- Physician migration to alternative dosage forms.
- Payer preference for lower-cost products.
- Loss of prescription volume before a Striant-specific generic entered.
- Difficulty supporting manufacturing economics for a small buccal product.
This distinction matters. Striant did not need a direct generic equivalent to lose market share. Therapeutic competition within the testosterone category was sufficient to weaken demand.
What formulation patents protected Striant?
Striant’s intellectual-property value was tied primarily to its buccal delivery technology, mucoadhesive composition and method of delivering testosterone through the oral mucosa. Product protection for a dosage form of this type can involve:
- Composition-of-matter claims covering the mucoadhesive matrix.
- Formulation claims covering testosterone loading and excipients.
- Device or system claims covering the buccal unit.
- Method claims covering administration to the gum.
- Manufacturing claims covering tablet formation, coating or release characteristics.
The commercial value of those claims depended on whether a competitor needed to use the same formulation architecture. Alternative buccal systems, different excipient combinations or different testosterone delivery routes could reduce the practical scope of protection.
No active biosimilar barrier existed because Striant was not a biologic. Manufacturing barriers were also moderate rather than extreme. A buccal product requires specialized formulation and adhesion testing, but it does not present the same manufacturing complexity as a sterile injectable biologic.
What patent litigation affected Striant?
Striant did not develop a major litigation profile that materially changed the testosterone market. The principal business risks were commercial rather than litigation-driven.
There is no widely documented settlement agreement involving Striant that created a major delayed generic-entry event. There is also no public record of Striant litigation producing a market outcome comparable with settlements involving large testosterone franchises.
The absence of major litigation reflects the product’s economics. Patent litigation is expensive, and a small or declining product must generate sufficient expected value to justify enforcement or challenge costs.
Which companies challenged or competed with Striant?
Striant faced competition from manufacturers of testosterone products rather than from a single direct rival.
Relevant competitive groups included:
- AbbVie, through AndroGel.
- Endo Pharmaceuticals and related entities, through testosterone replacement products.
- Eli Lilly, through Axiron during its commercial period.
- Generic manufacturers of testosterone gels, injections and patches.
- Manufacturers of testosterone pellets and newer oral testosterone products.
The competitive landscape shifted toward products with lower patient friction, established reimbursement and larger sales forces. Striant’s specialized route of administration did not provide enough clinical or economic advantage to overcome those factors.
What licensing deals affected Striant?
Columbia Laboratories relied on licensing and commercialization arrangements as part of its business model. Striant’s commercial history included external relationships involving product rights, manufacturing and distribution rather than a fully integrated large-pharmaceutical commercial platform.
The economic effect of such arrangements was mixed:
- Licensing could reduce the cost of building a sales infrastructure.
- External commercialization could improve reach.
- Royalty or revenue-sharing obligations could reduce net product economics.
- A small product could become less attractive to a licensee as sales declined.
- Changes in corporate ownership or portfolio strategy could accelerate withdrawal.
Striant’s limited scale reduced its bargaining power in later-stage licensing discussions. A licensee would likely prioritize products with larger growth potential or stronger payer positioning.
What generic launch scenarios existed for Striant?
Three generic-entry scenarios were commercially plausible:
Direct buccal generic
A manufacturer could seek approval for a therapeutically equivalent testosterone buccal system. This route would face formulation, adhesion, release and bioequivalence challenges. The market opportunity would still be limited by the size of the remaining Striant prescription base.
Therapeutic substitution
Patients could be moved to generic testosterone injections, gels or patches. This was the most important effective generic threat because substitution did not require a direct Striant-equivalent product.
No commercially viable generic
A generic manufacturer could obtain regulatory approval but decline broad commercialization if the market were too small. Manufacturing complexity and low prescription volume could produce insufficient margins.
The third scenario is common for discontinued niche dosage forms. Regulatory approval does not guarantee a sustainable commercial launch.
How strong was the Striant patent estate?
Striant’s patent estate was moderate as a technical matter but weak as a long-term commercial asset.
Strengths
- Differentiated buccal delivery platform.
- Potential formulation and method-of-use protection.
- FDA-approved product with defined pharmacokinetic characteristics.
- Manufacturing know-how in mucoadhesive dosage forms.
Weaknesses
- Small commercial market.
- Twice-daily administration.
- Local tolerability concerns.
- Competition from established testosterone products.
- Limited opportunity for indication expansion.
- Lack of biologic manufacturing barriers.
- Declining value after commercial discontinuation.
Patent strength should therefore be separated from franchise strength. Striant may have had technically defensible formulation claims, but those claims did not create a durable, high-value commercial position.
What is the outlook for Striant revenue?
Striant has no meaningful forward revenue trajectory as an active branded U.S. growth product. The relevant financial conclusion is that recurring branded revenue declined with commercial availability and ultimately approached zero following discontinuation.
Potential residual revenue could arise from:
- Limited remaining inventory.
- Foreign-market sales, if any rights remained active.
- A third-party relaunch.
- A generic or authorized-generic strategy.
- Licensing of buccal testosterone technology rather than continued sale of Striant itself.
Those opportunities would require a new commercial strategy and would not restore the original product’s historical positioning without changes to dosing, tolerability, reimbursement or distribution.
Key Takeaways
- Striant was a 30 mg testosterone buccal system approved by FDA in 2003.
- Its twice-daily gum application limited adherence and commercial appeal.
- The product competed against gels, injections, patches, pellets and later oral testosterone products.
- Commercial erosion was driven primarily by dosage-form competition and weak market adoption.
- Striant was not a biologic, so biosimilar risk did not apply.
- No major Paragraph IV litigation or settlement materially shaped the product’s market.
- Its patent value centered on buccal formulation and delivery technology.
- The product’s financial trajectory was declining revenue followed by commercial discontinuation.
- Current value is more likely to reside in formulation know-how or licensing rights than in branded Striant sales.
- Generic competition was economically less important than therapeutic substitution by established testosterone products.
FAQs About Striant Market Dynamics
Is Striant still available in the United States?
Striant is listed as discontinued in FDA drug-product records and is not an active growth product in the U.S. market.[4]
Did Striant have biosimilar competition?
No. Striant contained testosterone, a small-molecule drug. Competition would occur through generic approval or alternative testosterone products, not biosimilar pathways.
Was Striant more effective than testosterone gel?
Striant provided a different delivery route, but there is no broad commercial evidence that it offered a clinically meaningful advantage over established testosterone gels. Its twice-daily administration and oral-site tolerability reduced its practical competitiveness.
Could a company relaunch Striant?
A relaunch would require commercial rights, manufacturing capability, regulatory compliance and a viable reimbursement strategy. A relaunch based on the original dosage form would face the same adherence and competition problems.
Why did Striant fail commercially despite FDA approval?
FDA approval established safety and efficacy for its indication but did not solve the product’s market-positioning problems. Twice-daily application, gum irritation, limited prescriber familiarity and strong competition constrained adoption.
References
-
U.S. Food and Drug Administration. (2003). Striant testosterone buccal system: Prescribing information, NDA 021306. FDA.
-
Columbia Laboratories, Inc. (2008). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Columbia Laboratories, Inc. (2012). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). FDA-approved drug products discontinued from marketing. FDA.
